Literature DB >> 30400020

Differential efatutazone's impact on mammary neoplasia dependent upon Brca1 dose.

Sahar J Alothman1,2, Weisheng Wang2, Shan Chao1,2, Bhaskar V Kallakury3,4, Edgar S Díaz-Cruz2,5, Priscilla A Furth2,4,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30400020      PMCID： PMC6944742          DOI： 10.1530/ERC-18-0299

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN： 1351-0088            Impact factor:   5.678


× No keyword cloud information.
  9 in total

1.  Responsiveness of Brca1 and Trp53 Deficiency-Induced Mammary Preneoplasia to Selective Estrogen Modulators versus an Aromatase Inhibitor in Mus musculus.

Authors:  Sahar J Alothman; Weisheng Wang; David S Goerlitz; Md Islam; Xiaogang Zhong; Archana Kishore; Redha I Azhar; Bhaskar V Kallakury; Priscilla A Furth
Journal:  Cancer Prev Res (Phila)       Date:  2017-03-10

Review 2.  BRCA1 and BRCA2: different roles in a common pathway of genome protection.

Authors:  Rohini Roy; Jarin Chun; Simon N Powell
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

3.  The PPARγ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ.

Authors:  Virginie Ory; William B Kietzman; Jacob Boeckelman; Bhaskar V Kallakury; Anton Wellstein; Priscilla A Furth; Anna T Riegel
Journal:  Breast Cancer Res Treat       Date:  2018-01-19       Impact factor: 4.872

Review 4.  Brown vs white adipocytes: the PPARgamma coregulator story.

Authors:  Arjen Koppen; Eric Kalkhoven
Journal:  FEBS Lett       Date:  2010-06-30       Impact factor: 4.124

5.  Anticancer activities of PPARγ in breast cancer are context-dependent.

Authors:  Jin-Tang Dong
Journal:  Am J Pathol       Date:  2013-04-22       Impact factor: 4.307

6.  The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.

Authors:  Rebecca E Nakles; Bhaskar V S Kallakury; Priscilla A Furth
Journal:  Am J Pathol       Date:  2013-05-08       Impact factor: 4.307

7.  Pioglitazone, a PPARγ agonist, suppresses CYP19 transcription: evidence for involvement of 15-hydroxyprostaglandin dehydrogenase and BRCA1.

Authors:  Kotha Subbaramaiah; Louise R Howe; Xi Kathy Zhou; Peiying Yang; Clifford A Hudis; Levy Kopelovich; Andrew J Dannenberg
Journal:  Cancer Prev Res (Phila)       Date:  2012-07-10

8.  Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis.

Authors:  Sabine Heublein; Doris Mayr; Alfons Meindl; Alexandra Kircher; Udo Jeschke; Nina Ditsch
Journal:  J Exp Clin Cancer Res       Date:  2017-04-20

9.  A Novel High-Throughput 3D Screening System for EMT Inhibitors: A Pilot Screening Discovered the EMT Inhibitory Activity of CDK2 Inhibitor SU9516.

Authors:  Kazuya Arai; Takanori Eguchi; M Mamunur Rahman; Ruriko Sakamoto; Norio Masuda; Tetsuya Nakatsura; Stuart K Calderwood; Ken-Ichi Kozaki; Manabu Itoh
Journal:  PLoS One       Date:  2016-09-13       Impact factor: 3.240
  9 in total
  1 in total

Review 1.  Peroxisome proliferator-activated receptor gamma and BRCA1.

Authors:  Priscilla A Furth
Journal:  Endocr Relat Cancer       Date:  2019-02       Impact factor: 5.678
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.